Are These Biotech Penny Stocks On Your Watch List Today?
One of the most active industries right now is biotech & penny stocks have stood to benefit the most. Quite honestly, when you think about “novel” treatments, you’re talking about early-stage companies in many cases. With that, you can consider penny stocks among those “early-stage” / “development stage” organizations. Due to the fact that so many of these smaller companies tend to be more nimble simply due to the fact of lower overhead and more streamlined operating procedures, these biotechs tend to have an innate ability to progress through early-stage trials easier.
This isn’t to say that all penny stocks in biotech are this way. However, when you’re talking about Phase 1 and 2, possibly early-stage Phase 3, the smaller companies have much to offer. Further to this, from an investment perspective, once the basic trial concept if proven, many go on to sign multi-million and billion-dollar deals with the big pharma names we all know. This also opens the door for huge mergers and acquisitions opportunities. In this arena, we usually don’t see million-dollar buyouts; we see billion-dollar ones.
- Top Penny Stocks To Watch Right Now; 5 Testing October Highs
- Does Your List Of Penny Stocks To Buy Have These 5 On It In October?
Earlier this year, attention shifted from coronavirus to cancer and pain management. This came on the heels of Gilead’s $21 billion deal with Immunomedics. What’s more is that Gilead was willing to pay a premium in order to gain access to Immunomedics’ breast cancer platform. While that alone isn’t the source of continued momentum among biotech stocks, it is something investors haven’t forgotten about. This month, we’ve already seen significant progress being made with many of these companies. In light of this, will these biotech penny stocks be on your list for October?
Biotech Penny Stocks To Watch: GT Biopharma Inc.
GT Biopharma Inc. (GTBP Stock Report) remains in a steady uptrend. The last several weeks have proven to be fruitful both from a company and market perspective. GT’s treatment platform, TriKE™, is a combination protein. It bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially. It has also led to new first-in-human phase studies to treat leukemia but has been indicated for other immune diseases.
Late last month the company reported that the first patient enrolled at Dose Level 3 in its GTB-3550 TriKE™ Phase I/II clinical trial for acute myeloid leukemia. The findings were positive and included improvement in marrow cellularity, a decrease in AML blast levels, and improving platelet and red blood cell numbers. It’s important to note interim data and as such, GT’s finding here further supports continued efforts in this trial.
In addition to this, the company has expanded upon the TriKE™ platform, overall. Last week the company announced that Cytovance® Biologics signed a deal with GT to manufacture TriKE™ using Cytovance’s proprietary Keystone® bacterial or mammalian expression systems.
If successful, Cytovance stands to gain up to $6 million for its manufacturing services. In light of this, the company has recently brought on two more members to its Scientific Advisory Board. GT explained that it aims to also expand the therapeutic indications for TriKE ™ to non-hematologic cancers such as prostate.
Biotech Penny Stocks To Watch: Medigus Ltd.
Medigus Ltd. (MDGS Stock Report) was one of the biotech penny stocks discussed earlier this month. At the heart of the company, Medigus is a medical device company. It specializes in developing minimally invasive endosurgical tools and imaging solutions across medical and industrial applications. The recent excitement, however, came as the company has expanded its footprint to include eCommerce as well.
Last week, the company entered into the e-commerce business through a definitive agreement to acquire a controlling interest in Smart Repair Pro, Inc. and Purex, Inc., operating on the Amazon Marketplace. In an earlier press release, Liron Carmel, CEO of Medigus, said “This agreement is part of Medigus’ efforts to strengthen its two main fields of operation: medical operations which include the MUSE™ system, customized visualization solution through ScoutCam, Inc., and Polyrizon Ltd.’s bio-gels, and online operations through Gix Internet Ltd., Linkury Ltd., and these new e-commerce operations on the Amazon Marketplace. By leveraging our broad knowledge, experience, and capabilities, we continue to maximize our operations and value proposition.”
This week, MDGS stock continued surging after its latest development. Medigus announced that it was informed by Smart Repair Pro, Inc., that all of Amazon’s required regulatory processes were completed. This now allows for the opening of its store in 5 leading countries: UK, France, Italy, Germany, and Spain. Following this, Smart Repair Pro is readying the launch its brands for the first time in the European and UK market.
Biotech Penny Stocks To Watch: Regulus Therapeutics Inc.
Tegulus Therapeutics Inc. (RGLS Stock Report) updated the market today with its own key developments. The company announced that it had received a $5 million milestone and material payment from Sanofi. In August 2020, the company entered into an amendment with Sanofi concerning the receipt of potential milestones from Sanofi for its development of miR-21 programs.
Aside from this, the company’s been working to advance its RGLS4326 treatment in patients with Autosomal dominant polycystic kidney disease (ADPKD). It was already granted Orphan Drug Designation by FDA. The company’s planning the initiation of a Phase 1b study for safety, tolerability, and pharmacokinetics. However, no dates were finalized quite yet. The “second half of the year” is the last updated point on that timeline.
However, top-line results from a MAD clinical study completed in July showed RGLS4326 as well-tolerated and had no serious adverse events reported. Tuesday’s session, however, seems to have been fueled by the Sanofi news. In light of this development and the pending initiation of its Phase 1b trial, is RGLS on your list of penny stocks right now?
Biotech Penny Stocks To Watch: TransEnterix Inc.
TransEnterix Inc. (TRXC Stock Report) announced today that surgeons at Maastricht University Medical Center+ successfully operated on multiple pediatric patients utilizing the company’s Senhance® Surgical System. Accordingly, the company explained this was the first pediatric surgical program in the world to utilize Senhance®. It integrated digital laparoscopy with instruments as small as 3 mm into their standard of surgical care.
Prof. Dr. Wim van Gemert , Chairman of the Department of Pediatric Surgery, MUMC+ said, “As we have begun to utilize the Senhance System in multiple pediatric patients, including complex reconstructive procedures, we’ve found that the haptic feedback, precision and unique vision control system are advantages to our experience. This platform has a very promising future as a tool in the hands of pediatric surgeons.”
This adds to the progress that the company has realized with its Senhance® system. Last week, TransEnterix announced Toshima Hospital of the Tokyo Metropolitan Health and Hospitals Corporation has entered into an agreement to lease and utilize a Senhance® Surgical System.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), GT Biopharma is required to pay $200,000 per month for 4 months of services, $400,000 of which has already been paid for 2 months of services (first and last month) for a period from September 22, 2020 to January 22, 2021. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).